These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 9129864)

  • 1. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron.
    Saeedi M; Rashidy-Pour A
    Biomed Pharmacother; 2021 Jan; 133():110995. PubMed ID: 33232931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs.
    Grundman M; Corey-Bloom J; Thal LJ
    J Neural Transm Suppl; 1998; 53():255-75. PubMed ID: 9700663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward an early diagnosis and treatment of Alzheimer's disease.
    Nordberg A
    Int Psychogeriatr; 2003 Sep; 15(3):223-37. PubMed ID: 14756159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
    Doraiswamy PM
    CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.
    Hampel H; Mesulam MM; Cuello AC; Farlow MR; Giacobini E; Grossberg GT; Khachaturian AS; Vergallo A; Cavedo E; Snyder PJ; Khachaturian ZS
    Brain; 2018 Jul; 141(7):1917-1933. PubMed ID: 29850777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of Alpinia galanga (L.) fractions on Aβ(25-35) induced amnesia in mice.
    Hanish Singh JC; Alagarsamy V; Diwan PV; Sathesh Kumar S; Nisha JC; Narsimha Reddy Y
    J Ethnopharmacol; 2011 Oct; 138(1):85-91. PubMed ID: 21911048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease.
    Pimentel LS; Allard S; Do Carmo S; Weinreb O; Danik M; Hanzel CE; Youdim MB; Cuello AC
    J Alzheimers Dis; 2015; 47(2):373-83. PubMed ID: 26401560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression?
    Giacobini E
    Aging (Milano); 2001 Jun; 13(3):247-54. PubMed ID: 11442306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.
    Davidson M; Stern RG
    Psychiatr Clin North Am; 1991 Jun; 14(2):461-82. PubMed ID: 2062728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of the basal forebrain cholinergic dysfunction in pathogenesis of declarative memory disorder in Alzheimer's disease].
    Mukhin VN
    Ross Fiziol Zh Im I M Sechenova; 2013 Jun; 99(6):674-81. PubMed ID: 24459876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tramiprosate.
    Wright TM
    Drugs Today (Barc); 2006 May; 42(5):291-8. PubMed ID: 16801992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of natural products for the treatment of Alzheimer's disease.
    Noori T; Dehpour AR; Sureda A; Sobarzo-Sanchez E; Shirooie S
    Eur J Pharmacol; 2021 May; 898():173974. PubMed ID: 33652057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.